NanoViricides Secures $6 Million in Financing to Advance Antiviral Drug Pipeline

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biotechnology company, has secured approximately $6 million in new financing through a registered direct offering and concurrent private placement. The company entered into a securities purchase agreement with a single healthcare institutional investor for the purchase of 3,571,429 shares of common stock at $1.68 per share, generating expected gross proceeds of $6 million before expenses.

In a concurrent private placement, NanoViricides will issue Series A and Series B warrants, each allowing the purchase of up to 3,571,429 additional shares. The Series A warrants carry an exercise price of $1.75 per share and will be exercisable six months after issuance, expiring in two years. The Series B warrants have an exercise price of $2.00 per share, will be exercisable after six months, and expire in 5.5 years. The offering is expected to close on or about November 12, 2025, subject to customary closing conditions, with A.G.P./Alliance Global Partners acting as sole placement agent.

This financing is significant because it provides critical capital for NanoViricides to advance its pipeline of broad-spectrum antiviral nanomedicines at a time when the global healthcare sector continues to face challenges from respiratory viruses and emerging viral threats. The company plans to use the proceeds for working capital and general corporate purposes, with a primary focus on advancing its lead drug candidate, NV-387, into Phase II human clinical trials.

NV-387 represents a promising therapeutic approach as a broad-spectrum antiviral drug candidate being developed for multiple indications including RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's second advanced candidate, NV-HHV-1, targets the treatment of Shingles. Additional information about the company's technology and pipeline can be found at https://www.nanoviricides.com.

The importance of this funding extends beyond NanoViricides' immediate corporate needs. The development of broad-spectrum antiviral therapies addresses a critical gap in global healthcare preparedness. Current antiviral treatments typically target specific viruses, leaving healthcare systems vulnerable to new and emerging viral threats. NanoViricides' platform technology, based on intellectual property licensed from TheraCour Pharma, Inc., offers a novel approach that could potentially provide protection against multiple viral families.

The company holds exclusive worldwide perpetual licenses for several viral disease targets including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, and certain Coronaviruses. The company intends to pursue additional licenses for RSV, Poxviruses, and Enteroviruses if initial research proves successful. Investors can access the latest company updates through the newsroom at https://ibn.fm/NNVC.

This financing round demonstrates continued investor confidence in the nanoviricide platform technology at a time when the global pharmaceutical industry is increasingly focused on developing versatile antiviral solutions. The successful advancement of NanoViricides' pipeline could have significant implications for public health by providing new treatment options for multiple viral diseases that currently lack effective therapies or where existing treatments face limitations due to viral resistance or narrow spectrum of activity.